by MM360 Staff | May 24, 2025 | Publications
Clin Lymphoma Myeloma Leuk. 2025 Apr 3:S2152-2650(25)00105-3. doi: 10.1016/j.clml.2025.03.013. Online ahead of print. ABSTRACT PURPOSE: The increasing use of single-arm and nonrandomized trial designs in oncology aims to expedite patient access to novel treatments. To...
by MM360 Staff | May 17, 2025 | Publications
Syst Rev. 2025 May 16;14(1):113. doi: 10.1186/s13643-025-02804-4. ABSTRACT BACKGROUND: Daratumumab (Dara)-based regimens have been investigated in randomized controlled trials (RCTs) involving patients with newly diagnosed and previously untreated multiple myeloma...
by MM360 Staff | May 13, 2025 | Publications
Int J Hematol. 2025 May 13. doi: 10.1007/s12185-025-03998-y. Online ahead of print. ABSTRACT BACKGROUND: Sarcopenia, characterized by skeletal muscle loss, is increasingly recognized as a predictor of poor outcomes in hematologic malignancies. This study evaluated the...
by MM360 Staff | May 12, 2025 | Publications
Front Immunol. 2025 Apr 25;16:1565407. doi: 10.3389/fimmu.2025.1565407. eCollection 2025. ABSTRACT BACKGROUND: Multiple myeloma (MM) is a hematological malignancy with limited treatment options for patients with relapsed/refractory MM (RRMM). Teclistamab, a B-cell...
by MM360 Staff | May 8, 2025 | Publications
Cancer. 2025 May 15;131(10):e35896. doi: 10.1002/cncr.35896. ABSTRACT BACKGROUND: Allogeneic stem cell transplantation (allo-SCT) has curative potential and was previously considered by several experts superior to autologous stem cell transplantation (auto-SCT) for...
by MM360 Staff | Apr 17, 2025 | Publications
Int J Mol Sci. 2025 Apr 4;26(7):3369. doi: 10.3390/ijms26073369. ABSTRACT Multiple myeloma ranks as the second most common hematopoietic malignancy in terms of both incidence and mortality. Prognostic stratification is critical for optimizing therapeutic strategies,...
